News
Warm holiday wishes from IFIGENEIA!
May health and science come together for a brighter future in 2026! Warm holiday wishes from IFIGENEIA!
Meet the IFIGENEIA partner: University of Ljubljana
With a strong interdisciplinary foundation and decades of scientific excellence, the University of Ljubljana brings valuable expertise to the IFIGENEIA consortium, contributing to the project’s vision of advancing next-generation radioisotope technologies. The...
IFIGENEIA Interview: An Overview of Cancer Research with Prof. Dr. DABR. Joao Seco
In November 2025, Prof. Dr. DABR. Joao Seco held several lectures and presentations in Slovenia about cancer treatments from different perspectives. In the scope of his visit, he also shared his insights on how cancer research has developed in the past years and...
Meet the IFIGENEIA partner: Aristotle University of Thessaloniki
As one of Europe’s leading academic institutions, the Aristotle University of Thessaloniki (AUTH) plays a pivotal role in driving scientific excellence and innovation within the IFIGENEIA project. With its strong multidisciplinary foundation and longstanding research...
IFIGENEIA Presented at Major Panhellenic Biomedical Conferences
The co-organiser of the Aristotle Medical Forum 2024, in Thessaloniki, Prof Panagiotis Bamidis, President of the Hellenic Society of Biomedical Technology and head of the Medical Physics and Digital Innovation Lab of the School of Medicine of the Aristotle University...
New technologies for cancer treatment: FLASH, SFRT and TRNT (IFIGENEIA video lecture)
In the scope of the IFIGENEIA project, we hosted an invited lecture by Prof. Dr. DABR. Joao Seco on 11 November 2025 at the Faculty of Medicine, University of Ljubljana, Slovenia, on the topic: Next generation technologies that can impact cancer therapy: FLASH, SFRT...
Could COVID-19 mRNA vaccines help with cancer treatment in the future?
During the COVID-19 pandemic, mRNA vaccines became widely known to the general public. With their use, the immune system could recognise the virus and start creating antibodies to fight it. More precisely, mRNA (messenger ribonucleic acid) taught the immune system to...
First Meeting of the Slovenian IFIGENEIA Hub
Slovenian partners of the European project IFIGENEIA held their first meeting of the Slovenian Hub (SLO HUB) in Ljubljana earlier this spring, bringing together key stakeholders from nuclear physics, medical physics, radiology, radioisotope research, and...
EU actions for cancer prevention, diagnosis and treatment
Cancer is the second leading cause of death in Europe. Moreover, it's the leading cause of death for women and men under 65. In 2022, new cancer cases reached 2.7 million and the incidence increased for 2.3% in comparison with 2020. In the same period, estimated...
Discover the First IFIGENEIA Newsletter!
The IFIGENEIA project has launched the first edition of its newsletter—an engaging snapshot of how the consortium is laying the groundwork for a new era of medical radioisotope production in Europe. This debut issue opens with a warm welcome from the coordination team...
News
Warm holiday wishes from IFIGENEIA!
May health and science come together for a brighter future in 2026! Warm holiday wishes from IFIGENEIA!
Meet the IFIGENEIA partner: University of Ljubljana
With a strong interdisciplinary foundation and decades of scientific excellence, the University of Ljubljana brings valuable expertise to the IFIGENEIA consortium, contributing to the project’s vision of advancing next-generation radioisotope technologies. The...
IFIGENEIA Interview: An Overview of Cancer Research with Prof. Dr. DABR. Joao Seco
In November 2025, Prof. Dr. DABR. Joao Seco held several lectures and presentations in Slovenia about cancer treatments from different perspectives. In the scope of his visit, he also shared his insights on how cancer research has developed in the past years and...
Meet the IFIGENEIA partner: Aristotle University of Thessaloniki
As one of Europe’s leading academic institutions, the Aristotle University of Thessaloniki (AUTH) plays a pivotal role in driving scientific excellence and innovation within the IFIGENEIA project. With its strong multidisciplinary foundation and longstanding research...
IFIGENEIA Presented at Major Panhellenic Biomedical Conferences
The co-organiser of the Aristotle Medical Forum 2024, in Thessaloniki, Prof Panagiotis Bamidis, President of the Hellenic Society of Biomedical Technology and head of the Medical Physics and Digital Innovation Lab of the School of Medicine of the Aristotle University...
New technologies for cancer treatment: FLASH, SFRT and TRNT (IFIGENEIA video lecture)
In the scope of the IFIGENEIA project, we hosted an invited lecture by Prof. Dr. DABR. Joao Seco on 11 November 2025 at the Faculty of Medicine, University of Ljubljana, Slovenia, on the topic: Next generation technologies that can impact cancer therapy: FLASH, SFRT...
Could COVID-19 mRNA vaccines help with cancer treatment in the future?
During the COVID-19 pandemic, mRNA vaccines became widely known to the general public. With their use, the immune system could recognise the virus and start creating antibodies to fight it. More precisely, mRNA (messenger ribonucleic acid) taught the immune system to...
First Meeting of the Slovenian IFIGENEIA Hub
Slovenian partners of the European project IFIGENEIA held their first meeting of the Slovenian Hub (SLO HUB) in Ljubljana earlier this spring, bringing together key stakeholders from nuclear physics, medical physics, radiology, radioisotope research, and...
EU actions for cancer prevention, diagnosis and treatment
Cancer is the second leading cause of death in Europe. Moreover, it's the leading cause of death for women and men under 65. In 2022, new cancer cases reached 2.7 million and the incidence increased for 2.3% in comparison with 2020. In the same period, estimated...
Discover the First IFIGENEIA Newsletter!
The IFIGENEIA project has launched the first edition of its newsletter—an engaging snapshot of how the consortium is laying the groundwork for a new era of medical radioisotope production in Europe. This debut issue opens with a warm welcome from the coordination team...